A quantitative trait variant in Gabra2 underlies increased methamphetamine stimulant sensitivity

Area of Science:

• Neurogenetics
• Pharmacology
• Behavioral Genetics

Background:

• Psychostimulant use disorders, including those related to methamphetamine and cocaine, have a genetic basis that is not well understood.
• Identifying genetic factors is crucial for understanding addiction vulnerability and developing targeted treatments.

Purpose of the Study:

• To conduct a genome-wide quantitative trait locus (QTL) analysis to identify genetic variants associated with methamphetamine stimulant sensitivity.
• To pinpoint specific genes and genetic mechanisms underlying behavioral responses to psychostimulants.

Main Methods:

• Utilized a Reduced Complexity Cross (RCC) between C57BL/6 mouse substrains to map QTLs for methamphetamine-induced locomotor activity (speed and distance).
• Performed genome-wide QTL analysis, identified significant QTLs on chromosomes 11 and 5, and pinpointed candidate genes (Cyfip2, Gabra2).
• Employed cis-expression QTL mapping and CRISPR/Cas9 gene editing to validate the functional role of Gabra2 variants.

Main Results:

• A significant QTL for methamphetamine-induced speed was found on chromosome 11 near the Cyfip2 locus.
• A significant QTL for methamphetamine-induced distance traveled was identified on chromosome 5, associated with an intronic indel in Gabra2.
• CRISPR/Cas9 correction of the Gabra2 intronic indel reduced methamphetamine-induced locomotor activity, validating its role as a quantitative trait variant (QTV).

Conclusions:

• Reduced Complexity Crosses are effective for identifying causal variants underlying complex traits like psychostimulant sensitivity.
• The GABA-A receptor alpha-2 subunit (Gabra2) is implicated in psychostimulant addiction-relevant behaviors, supported by preclinical and human genetic studies.
• Findings have significant implications for research using the C57BL/6J mouse strain, a standard model in biomedical research, and for understanding psychostimulant use disorders.